Education
About Us
Working with TipRanks
Follow Us
Abbisko Cayman Limited (HK:2256)
:2256
RESEARCH TOOLSreports
2256 Stock Chart & Stats
Day’s Range― - ―
52-Week RangeHK$2.73 - HK$11.74
Previous CloseN/A
Volume927.00K
Average Volume (3M)3.70M
Market Cap
HK$7.24B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)181.3
Beta1.30
Next Earnings
Aug 04, 2025EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding680,105,350
10 Day Avg. Volume5,026,541
30 Day Avg. Volume3,700,168
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.00Price Target Upside3.38% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe MANEUVER trial demonstrated a 54% ORR in patients treated with pimicotinib compared to 3.2% for patients treated with placebo.
Financial PerformanceThe analyst's price target for Abbisko Therapeutics stock has been raised from HK$16.00 to HK$18.00.
Regulatory SubmissionThe company expects to submit an NDA for pimicotinib in Tenosynovial Giant Cell Tumor to the Chinese NMPDA and to the US FDA, demonstrating best-in-class efficacy in TGCT.
Bears Say
Market CompetitionMerck KGaA exclusively licensed commercialization rights for pimicotinib in several regions, with substantial potential payments and royalties.
Regulatory Approval ProcessThe company plans to start the registrational irpagratinib trial that will evaluate monotherapy in FGFR19+ hepatocellular carcinoma in China.
Abbisko Cayman Limited News
2256 FAQ
What was Abbisko Cayman Limited’s price range in the past 12 months?
Abbisko Cayman Limited lowest stock price was HK$2.73 and its highest was HK$11.74 in the past 12 months.
What is Abbisko Cayman Limited’s market cap?
Abbisko Cayman Limited’s market cap is HK$7.24B.
When is Abbisko Cayman Limited’s upcoming earnings report date?
Abbisko Cayman Limited’s upcoming earnings report date is Aug 04, 2025 which is in 3 days.
How were Abbisko Cayman Limited’s earnings last quarter?
Abbisko Cayman Limited released its earnings results on Mar 03, 2025. The company reported -HK$0.307 earnings per share for the quarter, beating the consensus estimate of -HK$0.428 by HK$0.121.
Is Abbisko Cayman Limited overvalued?
According to Wall Street analysts Abbisko Cayman Limited’s price is currently Undervalued.
Does Abbisko Cayman Limited pay dividends?
Abbisko Cayman Limited does not currently pay dividends.
What is Abbisko Cayman Limited’s EPS estimate?
Abbisko Cayman Limited’s EPS estimate is 0.43.
How many shares outstanding does Abbisko Cayman Limited have?
Abbisko Cayman Limited has 680,105,350 shares outstanding.
What happened to Abbisko Cayman Limited’s price movement after its last earnings report?
Abbisko Cayman Limited reported an EPS of -HK$0.307 in its last earnings report, beating expectations of -HK$0.428. Following the earnings report the stock price went up 4.809%.
Which hedge fund is a major shareholder of Abbisko Cayman Limited?
Currently, no hedge funds are holding shares in HK:2256
Abbisko Cayman Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$11.00 (3.38% Upside)
HK$11.00 (3.38% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
257.04%
12-Months-Change
Fundamentals
Return on Equity
1.43%
Trailing 12-Months
Asset Growth
-3.72%
Trailing 12-Months
Company Description
Abbisko Cayman Limited
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer. It also has other pipeline product candidates. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Ascletis Pharma, Inc.
―
HBM Holdings Ltd.
―
CStone Pharmaceuticals
―
Shandong Boan Biotechnology Company., Limited. Class H
―
Ownership Overview
―
Insiders
0.89%
Mutual Funds
― Other Institutional Investors
99.03% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---